Editas Medicine Inc
EDITHealthcare|Biotechnology|USA
$3.26
-0.03 (-0.76%)
Tangible Book
$0.05
Clinical Trials (5)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04853576 A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY) | Sickle Cell Disease, Hemoglobinopathies | P1P2 | Active | 45 | Open-label | — |
| NCT05444894 EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT) | Transfusion Dependent Beta Thalassemia, Hemoglobinopathies | P1P2 | Active | 9 | Open-label | — |
| NCT03872479 Single Ascending Dose Study in Participants With LCA10 | Leber Congenital Amaurosis 10, Inherited Retinal Dystrophies | P1P2 | Unknown | 34 | Open-label | EDIT-101 |
| NCT03396042 Natural History Study of CEP290-Related Retinal Degeneration | Blindness, Leber Congenital Amaurosis 10 | Completed | 26 | — | — | |
| NCT06363760 A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301 | Sickle Cell Disease, Transfusion-dependent Beta-Thalassemia | By Invite | 54 | — | — |